Aki Morikawa
Clinical Associate Professor of Internal Medicine
Internal Medicine, Hematology/Oncology
1500 E. Medical Center Drive, Med Inn C340
Ann Arbor, MI 48109-5848
[email protected]

Available to mentor

Aki Morikawa
Clinical Associate Professor
  • About
  • Qualifications
  • Research Overview
  • Recent Publications
  • About

    Institution: University of Michigan, Michigan Medicine/Rogel Cancer Center

    Specialization/Interest Area(s): Breast cancer, clinical and translational research, central nervous system metastases from solid tumors, medical oncologist.

    Bio: After earning her M.PH in Epidemiology and Biostatistics from Boston University of Public Health, Dr. Morikawa received her MD/Ph.D. at the Emory University School of Medicine in Atlanta. After completing her residency training at Emory, she completed fellowship training in Medical Oncology at Memorial Sloan Kettering Cancer Center in New York. In 2014, she joined the University of Michigan as Clinical Lecturer and was appointed Clinical Assistant Professor in Internal Medicine. Her clinical practice focuses on caring for patients with breast cancer. Her research involves clinical and translational investigations in breast cancer as well as brain and leptomeningeal metastases from solid tumors. She has conducted Her research has been supported by the American Society of Clinical Oncology (ASCO) Gianni Bonadonna Breast Cancer Fellowship, the ASCO Career Development Award, and the Susan G. Komen Career Catalyst Research Grant. At the University of Michigan, she is involved in multidisciplinary central nervous system metastases clinical and translational research. She actively collaborates with laboratory-based experts and clinical investigators from neurosurgery, radiation oncology, neuro-oncology, neuroradiology, and pathology.

    Qualifications
    • Fellowship
      Memorial Sloan Kettering Cancer Center, Medical Oncology, 2014
    • Residency
      Emory University, Internal Medicine, 2011
    • MD, PhD
      Emory University School of Medicine, 100 Woodruff Circle, 2008
    • MPH
      Boston University School of Public Health, Boston, 2000
    • M.Mus.
      Boston University School of Arts, Boston, 1998
    • B.Mus.
      Boston University School of Arts, Boston, 1996
    Research Overview

    1, New therapy for brain and leptomeningeal metastases from breast cancer.
    2. Epidemiology and molecular profiling of central nervous system metastases from solid tumors.
    3. Biomarker development for central nervous system metastasis from solid tumors.
    4. Preclinical models to examine central nervous system metastasis from solid tumors.
    5. New therapy for breast cancer.

    Recent Publications See All Publications
    • Journal Article
      Targeting fatty acid synthase in preclinical models of TNBC brain metastases synergizes with SN-38 and impairs invasion.
      Serhan HA, Bao L, Cheng X, Qin Z, Liu C-J, Heth JA, Udager AM, Soellner MB, Merajver SD, Morikawa A, Merrill NM. NPJ Breast Cancer, 2024 Jun 10; 10 (1): 43 DOI:10.1038/s41523-024-00656-0
      PMID: 38858374
    • Proceeding / Abstract / Poster
      Examining molecular landscape and drug sensitivity profiles of patient-derived xenografts from resected brain metastases.
      Morikawa A, Rastogi T, Ulintz P, Serhan H, Nieblas-Bedolla E, Heth J, Cheng X, Bao L, Udager AM, Soellner M, Merrill N, Merajver SD. Journal of Clinical Oncology, 2024 Aug 10; 42 (23_suppl): 28 - 28. DOI:10.1200/jco.2024.42.23_suppl.28
    • Proceeding / Abstract / Poster
      H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).
      Hamilton EP, Pluard TJ, Wang JS, Morikawa A, Johnston SRD, Dees EC, Vaklavas C, Armstrong AC, Munster PN, Unni N, Wright GLS, Kayali F, Song T, Rong Y, Yamaguchi K, Juric D. Journal of Clinical Oncology, 2024 Jun 1; 42 (16_suppl): 1015 - 1015. DOI:10.1200/jco.2024.42.16_suppl.1015
    • Proceeding / Abstract / Poster
      Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC041: A phase II study of alisertib in endocrine resistant metastatic breast cancer (MBC).
      Giridhar K, Suman VJ, Tang X, Ye H, Campbell J, Mayer EL, Karuturi MS, Morikawa A, Kimmick GG, Isaacs C, Young Oh S, Clark AS, Park BH, Bucheit LA, Tsai J, Ingle JN, Goetz MP, D'assoro AB, Kalari KR, Haddad TC. Journal of Clinical Oncology, 2024 Jun 1; 42 (16_suppl): 1037 - 1037. DOI:10.1200/jco.2024.42.16_suppl.1037
    • Proceeding / Abstract / Poster
      Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results.
      O'Brien BJ, Murthy RK, Berry DA, Singareeka Raghavendra A, Gule-Monroe M, Johnson JM, Schwartz-Gomez J, Topletz-Erickson A, Lobbous M, Melisko ME, Morikawa A, Ferguson SD, de Groot JF, Krop IE, Valero V, Rimawi MF, Wolff AC, Tripathy D, Lin NU, Stringer-Reasor EM. Journal of Clinical Oncology, 2024 Jun 1; 42 (16_suppl): 2018 - 2018. DOI:10.1200/jco.2024.42.16_suppl.2018
    • Proceeding / Abstract / Poster
      Abstract PO2-16-01: Molecular correlates of drug response to guide therapy in triple-negative breast cancer
      Merrill N, Vandecan N, Apfel A, Serhan H, Ulintz P, Bao L, Cheng X, Morikawa A, Merajver S, Soellner M. Cancer Research, 2024 May 2; 84 (9_Supplement): po2-16-01-po2-16-01 DOI:10.1158/1538-7445.sabcs23-po2-16-01
    • Proceeding / Abstract / Poster
      Abstract PO3-06-12: Targeting Fatty Acid Synthase in Brain Metastatic Triple-negative Breast Cancer
      Serhan H, Bao L, Cheng X, Soellner M, Merajver S, Morikawa A, Merrill N. Cancer Research, 2024 May 2; 84 (9_Supplement): po3-06-12-po3-06-12 DOI:10.1158/1538-7445.sabcs23-po3-06-12
    • Proceeding / Abstract / Poster
      Abstract PO3-18-12: Results from a first-in-human study of DAN-222, a novel high-capacity drug conjugate in metastatic breast cancer as monotherapy and in combination with a PARPi [NCT05261269]
      Hurvitz S, Hamilton E, Pluard T, Morikawa A, Soliman H, Yeung K, Brufsky A, Tiersten A, Razaq W, Foye K, Hagerty T. Cancer Research, 2024 May 2; 84 (9_Supplement): po3-18-12-po3-18-12 DOI:10.1158/1538-7445.sabcs23-po3-18-12